Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Tryp Therapeutics Inc (TRYP.CN)

Tryp Therapeutics Inc (TRYP.CN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 40,455
  • Shares Outstanding, K 66,320
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade TRYP.CN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings -0.05 on 02/28/21
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.445 +37.08%
on 07/12/21
0.620 -1.61%
on 07/30/21
+0.090 (+17.31%)
since 06/30/21
3-Month
0.445 +37.08%
on 07/12/21
0.850 -28.24%
on 05/06/21
-0.080 (-11.59%)
since 04/30/21

Most Recent Stories

More News
Companies Smashing the Psychedelic Ceiling

/PRNewswire/ -- It's early on in a burgeoning market, but there is certainly reason to be optimistic about the future of psychedelic medicines as a promising treatment for a broad spectrum of diseases...

TRYP.CN : 0.610 (+5.17%)
TRYPF : 0.4950 (+5.32%)
SEEL : 2.25 (-2.60%)
FTRP.TO : 7.74 (+7.50%)
FTRPF : 5.7460 (-2.32%)
Tryp Therapeutics Announces Q3 2021 Financial Results

San Diego, California--(Newsfile Corp. - July 28, 2021) - (CSE: TRYP) (OTCQB: TRYPF) ("" or the ""), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical...

TRYP.CN : 0.610 (+5.17%)
TRYPF : 0.4950 (+5.32%)
Psilocybin May Be the Key to Resolving the Global Obesity Epidemic

The global obesity issue is bursting at the seams. According to the World Health Organization, obesity ...

CLXPF : 3.0500 (+10.11%)
MMEDF : 4.6900 (+33.24%)
CMPS : 35.48 (-1.25%)
NMDBF : 0.1227 (+9.55%)
TRYP.CN : 0.610 (+5.17%)
NEON.CN : 0.145 (+3.57%)
Psychedelics -- Not Just for Mental Health Anymore

/PRNewswire/ -- In , Congress created what is known as Breakthrough Therapy designation, a distinction that affords biotechnology and pharmaceutical companies an expedited review process for experimental...

ATAI : 15.50 (-3.49%)
TRYP.CN : 0.610 (+5.17%)
TRYPF : 0.4950 (+5.32%)
CMPS : 35.48 (-1.25%)
MNMD : 3.06 (+0.99%)
CLXPF : 3.0500 (+10.11%)
Tryp Therapeutics Appoints Robin Carhart-Harris, Ph.D. as SAB Chairman and Adds Daniel Clauw, M.D. as Scientific Advisor

San Diego, California--(Newsfile Corp. - July 26, 2021) - (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical...

TRYP.CN : 0.610 (+5.17%)
TRYPF : 0.4950 (+5.32%)
Psychedelics Gain More Traction as New Research Aims to Address Chronic Pain and Mental Illness

/PRNewswire/ -- The early 1970s saw psychedelics and psilocybin products made illegal in the US in the war on drugs. Decades later, new research indicates the medical potential of psilocybin and psychedelics...

LKYSF : 0.7778 (+4.08%)
SEEL : 2.25 (-2.60%)
NUMI.VN : 0.970 (+4.30%)
MNMD : 3.06 (+0.99%)
MYCOF : 0.3785 (+8.14%)
TRYP.CN : 0.610 (+5.17%)
TRYPF : 0.4950 (+5.32%)
Tryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of Michigan

San Diego, California--(Newsfile Corp. - July 21, 2021) - (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical...

TRYP.CN : 0.610 (+5.17%)
TRYPF : 0.4950 (+5.32%)
Tryp Therapeutics to Host Q3 Investor Day on July 29, 2021

San Diego, California--(Newsfile Corp. - July 15, 2021) - (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical...

TRYP.CN : 0.610 (+5.17%)
TRYPF : 0.4950 (+5.32%)
Tryp Therapeutics Partners with the University of Michigan to Evaluate Proprietary Formulations

San Diego, California--(Newsfile Corp. - July 7, 2021) - (CSE: TRYP) (OTCQB:TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical...

TRYP.CN : 0.610 (+5.17%)
TRYPF : 0.4950 (+5.32%)
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Differentiated by Clinical Trials, World-Class Management

NetworkNewsAudio - Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) announces the availability of a broadcast titled, "GW Pharma Sells for Bilions; Psychedelic Company Following Similar Path."

TRYP.CN : 0.610 (+5.17%)
TRYPF : 0.4950 (+5.32%)

Key Turning Points

3rd Resistance Point 0.653
2nd Resistance Point 0.637
1st Resistance Point 0.623
Last Price 0.610
1st Support Level 0.593
2nd Support Level 0.577
3rd Support Level 0.563

See More

52-Week High 1.200
Fibonacci 61.8% 0.912
Fibonacci 50% 0.822
Fibonacci 38.2% 0.733
Last Price 0.610
52-Week Low 0.445

See More

Business Summary

Tryp Therapeutics Inc is a pharmaceutical company focused on identifying and developing clinical-stage compounds for orphan diseases and other diseases with high unmet medical needs. The company's main development program PFN program, is designed to treat neuropsychiatric disorders through the dosing...

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar